Tolerability of curcumin in pediatric inflammatory bowel disease: A forced-dose titration study

Journal of Pediatric Gastroenterology and Nutrition

Volumn 56, Issue 3, 2013, Pages 277-279

  Suskind, David L ^a   Wahbeh, Ghassan ^a   Burpee, Tyler ^a   Cohen, Morty ^c   Christie, Dennis ^a   Weber, Wendy ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Pharmacy Department   (United States)

Author keywords

complementary alternative medicine; Crohn disease; curcumin; inflammatory bowel disease; pediatrics; turmeric; ulcerative colitis

Indexed keywords

CURCUMIN; MESALAZINE; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; ADULT; ALTERNATIVE MEDICINE; ARTICLE; CHILD; CLINICAL ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; FLATULENCE; HUMAN; LABORATORY TEST; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS; ULCERATIVE COLITIS ACTIVITY INDEX;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; CROHN DISEASE; CURCUMIN; DIETARY SUPPLEMENTS; FEMALE; FLATULENCE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MEDICINE, AYURVEDIC; MESALAMINE; PILOT PROJECTS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

CURCUMA LONGA;

EID: 84874950762     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318276977d     Document Type: Article

References (16)

1. Podolsky DK. Pride and prejudice: Inflammatory bowel disease models and drug development. Curr Opin Gastroenterol 2000;16:295-6
2. Ramsewak RS, DeWitt DL, Nair MG. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. Phytomedicine 2000;7:303-8
3. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995;49:1551-6
4. Kang BY, Chung SW, Chung W, et al. Inhibition of interleukin-12 production in lipopolysaccharide-Activated macrophages by curcumin. Eur J Pharmacol 1999;384:191-5
5. Xu YX, Pindolia KR, Janakiraman N, et al. Curcumin inhibits IL1 alpha and TNF-Alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol 1997;11:49-62
6. Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric crohn disease activity index: A prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416-21
7. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study. Gastroenterology 2007;133:423-32
8. Eigner D, Scholz D. Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. J Ethnopharmacol 1999; 67:1-6
9. Shah BH, Nawaz Z, Pertani SA, et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-Activating factor- And arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2 signaling. Biochem Pharmacol 1999; 58:1167-72
10. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900
11. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980; 71:632-4
12. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 1986;24:651-4
13. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci 2005;50:2191-3
14. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebocontrolled trial. Clin Gastroenterol Hepatol 2006;4:1502-6
15. Day AS, Whitten KE, Bohane TD. Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease. J Paediatr Child Health 2004;40:681-4
16. Wong AP, Clark AL, Garnett EA, et al. Use of complementary medicine in pediatric patients with inflammatory bowel disease: Results from a multicenter survey. J Pediatr Gastroenterol Nutr 2009;48:55-60